




VINCOV-19, an antidote against SARS-CoV-2

Inventors: Nooruddin Khan & Krishnan H Harshan, School of Life sciences, UoH & CSIR-CCMB, Hyderabad

The DST-Technology Enabling Centre at University of Hyderabad (DST-UoH-TEC) contributed to the technology transfer of VinCov-19, India's first antidote and a cure against SARS-CoV-2 virus. The UoH-TEC helped Dr. Nooruddin (PI of the project) in identifying the Industrial partner and assisted in formulating the proposal for the next phase. The UoH and the Centre for Cellular and Molecular Biology (CCMB) in collaboration with VINS Bioproducts Limited, a leading immunological company (Hyderabad) successfully completed the Phase-2 Clinical Trials of VINCOV-19.

VINCOV-19 is an antibody fragment-based (Fab₂) product that was obtained from horses after immunization with inactivated SARS-CoV-2 virus in combination with adjuvants and later purified and proteolytically processed to get high purity F(ab')₂. The F(ab')₂ showed a high neutralizing capacity against the internalization of SARS-CoV-2 to lung cells and render maximum clinical benefits during the early stages of the



disease. This product is transferred to VINS Bio Products Limited, Hyderabad, and approved by DCGI, India for clinical trials on 27 April 2021. The Phase 2 Clinical Trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations. VINCOV-19 is now ready for market authorization and for simultaneous Phase 3 Clinical Trials. *Read more* (<https://herald.uohyd.ac.in/vincov-19-an-antidote-against-sars-cov-2-developed-by-uoh-ccmb-and-vins-receives-dcgi-approval-to-start-clinical-trials/>)